<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215588</url>
  </required_header>
  <id_info>
    <org_study_id>7774/16.07.2019</org_study_id>
    <nct_id>NCT04215588</nct_id>
  </id_info>
  <brief_title>Heparin and Protamine Titration in Cardiac Surgery Under Minimal Invasive Extracorporeal Circulation</brief_title>
  <official_title>Heparin and Protamine Titration Using Optical Detection Technology in Patients Undergoing Cardiac Surgery Under Minimal Invasive Extracorporeal Circulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      During a cardiac surgery under cardiopulmonary bypass it is essential that an appropriate
      level of anticoagulation is accomplished. To achieve this, the patient is administered
      heparin. After completion of the surgery, protamine is given to reverse the anticoagulant
      action of heparin. In this prospective clinical study the researchers will investigate the
      impact of the two different methods to calculate the required dosage of heparin and
      protamine; the individualized calculation computed by the Hemostasis Management System Plus
      (HMS Plus, Medtronic, Minneapolis, MN) device and the weight based. The investigators
      hypothesize that the aforementioned methods result in different dosages and will elaborate on
      their impact on postoperative bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total heparin dose</measure>
    <time_frame>operation duration</time_frame>
    <description>Heparin dose measured in IU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total protamine dose</measure>
    <time_frame>At the end of the cardiopulmonary bypass</time_frame>
    <description>Protamine dose measured in mg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cells transfusion</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Red Blood Cells transfusion measured in units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cells transfusion</measure>
    <time_frame>24 hours after the end of the operation</time_frame>
    <description>Red Blood Cells transfusion measured in units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen concentrate transfusion</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Fibrinogen concentrate transfusion measured in g</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen concentrate transfusion</measure>
    <time_frame>24 hours after the end of the operation</time_frame>
    <description>Fibrinogen concentrate transfusion measured in g</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin Complex Concentrate transfusion</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Prothrombin Complex Concentrate transfusion measured in IU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin Complex Concentrate transfusion</measure>
    <time_frame>24 hours after the end of the operation</time_frame>
    <description>Prothrombin Complex Concentrate transfusion measured in IU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets transfusion</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Platelet transfusion measured in units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets transfusion</measure>
    <time_frame>24 hours after the end of the operation</time_frame>
    <description>Platelet transfusion measured in units</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiopulmonary Bypass</condition>
  <arm_group>
    <arm_group_label>Individualized heparin and protamine titration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The device Hemostasis Management System Plus (Medtronic, Minneapolis, MN) will be used to determine the patients' sensitivity to heparin and its concentration in whole blood. Then, it will automatically calculate the necessary dose for anticoagulation during bypass. The protamine dose to eliminate heparin effect will be calculated from the remaining heparin concentration (0.75mg/100 International Units circulating heparin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Activated Clotting Time guided heparin and protamine dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heparin initial dose will be determined according to the patients' weight to achieve a required Activated Clotting Time (ACT) to initiate cardiopulmonary bypass. Subsequent doses of heparin will be administered according to ACT and protamine dose will be calculated from total heparin dose (0.75mg protamine/100 International Units heparin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemostasis Management System Plus</intervention_name>
    <description>Hemostasis Management System Plus (Medtronic, Minneapolis, MN) is a point of care device useful in the management of heparinization during bypass. It estimates the individual heparin dose response and calculates heparin concentration (IU/ml) in whole blood.</description>
    <arm_group_label>Individualized heparin and protamine titration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Activated Coagulation Timer System Plus</intervention_name>
    <description>The Activated Coagulation Timer System Plus device calculates the Activated Clotting Time (ACT) in seconds.</description>
    <arm_group_label>Activated Clotting Time guided heparin and protamine dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  elective cardiac surgery under cardiopulmonary bypass

        Exclusion Criteria:

          -  known blood disorder

          -  contraindication to heparin administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eleni Argiriadou, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eleni Argiriadou, Dr</last_name>
    <phone>+306973219190</phone>
    <email>argiriadou@auth.gr</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 29, 2019</study_first_submitted>
  <study_first_submitted_qc>December 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>January 1, 2020</last_update_submitted>
  <last_update_submitted_qc>January 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Anna Gkiouliava</investigator_full_name>
    <investigator_title>PhD candidate</investigator_title>
  </responsible_party>
  <keyword>anticoagulation</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

